DRTS (33) PRCT (48) AORT (54) TNDM (35) ⌘ Pro Terminal →

Bioventus Inc. (Class A) (BVS) — RQD Stock Rating Cockpit

$14.87 +1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Bioventus Inc. (Class A) (BVS) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $1.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BVS)Realized 20D OHLCV Swing Band: ±8.6%

RSI-14 MOMENTUMNEUTRAL RANGE

43.930 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.25>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE89% OF RANGE

L: $6$14.87H: $16

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (68% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on BVS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

10.4% ROIC with 68.3% gross margin and 5.77% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.25 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (67)

25/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like BVS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BVS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.66%⚡ TESTING RESISTANCE

2026-10-30O $14.84H $14.87L $13.32C $14.87VOL 666.7K

RES: $15.36SUP: $12.85SMA50: $13.70SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BVS Butterfly Map → + Track BVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

39.0%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BVS)

Health Care Rank #129 of 1016 ⚔️ DRTS vs BVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BVS vs. DRTS, PRCT, AORT, TNDM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bioventus Inc. (Class A) (BVS) ranks #129 by composite RQD confidence (66/100, grade C+) and #332 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BVS ACTIVE Bioventus Inc. (Class A)	C+	66/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	Benchmark Subject
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-bvs →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-bvs →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-bvs →
TNDM Tandem Diabetes Care Inc.	D-	35/100	—	53.8%	-35.0%	+0.56%	$1.38B	/tndm-vs-bvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001665988

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bioventus Inc. (Class A) (BVS) reported GAAP revenue of $568.1M (-0.9% vs. FY2024 revenue of $573.3M , and +10.9% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of $74.7M, and free cash flow of $72.1M (+90.8% YoY). On the balance sheet, BVS closed FY2025 with $683.6M in total assets against $279.0M in total debt (Altman Z-Score: 2.25, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$568.1M	$22.7M	$74.7M	$72.1M	$683.6M	$279.0M
FY2024 (FY)	2024-12-31	$573.3M	-$36.1M	$38.8M	$37.8M	$728.0M	$308.3M
FY2023 (FY)	2023-12-31	$512.3M	-$156.2M	$15.3M	$15.3M	—	—

3. BVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bioventus Inc. (Class A) (NASDAQ: BVS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $14.87 (+1.50% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BVS ranks #129 in composite RQD confidence.

How does BVS compare to DRTS and PRCT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BVS carries a Roarable C+ (66/100 RQD), trailing P/E of 55.0x, gross margin of 68.3%, and ROIC of 10.4%. By comparison, DRTS (Alpha Tau Medical Ltd.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and PRCT (PROCEPT BioRobotics Corporation) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BVS?

Per BVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001665988), Bioventus Inc. (Class A) generated $568.1M in revenue (-0.9% YoY), $22.7M in net income, and $72.1M in free cash flow against $683.6M in total assets and $279.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BVS trading relative to its 50-day, 200-day, and 52-week technical levels?

BVS last traded at $14.87 (+1.50% on volume of 444,933 shares), positioning the stock +8.54% above its 50-day simple moving average ($13.70) and +36.42% above its 200-day simple moving average ($10.90). Across its 52-week range of $6.47 to $15.89, BVS sits at the 89.2% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($13.59 to $16.15).

BVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BVS stock right now?

Bioventus Inc. (Class A) (BVS) currently earns a Roarable Rating of C+ (Hold — HOLD) with 66/100 RQD Confidence. Solid 68% profit margin (10% return on capital), mixed timing at 55x P/E—hold if owned, no rush to chase.

What is BVS's 12-month price target and RQD AI Jury consensus?

BVS's 12-month base price target is $15.41 (range $12.02 to $18.18), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BVS RQD Cockpit BVS 12M Forecast BVS Earnings & Move BVS Dividends & DRIP BVS Insiders & 13F BVS Whale Options BVS Profit Sankey BVS News & Why